ConCallIQ
Go Pro
ROSSARIBIOTECH Information Technology 30 Apr 2026

Rossari Biotech Ltd — Q4 FY26

Rossari Biotech delivered a strong Q4 FY26 with revenue of ₹684.9 crore (+18% YoY) and EBITDA of ₹77.3 crore (+11% YoY), marking the highest-ever quarterly revenue and EBITDA.

neutral medium
Compare with...
Revenue ₹685 Cr +18%
EBITDA ₹77 Cr +11%
PAT ₹46 Cr
EBITDA Margin 11.3% -70bps
Duration 60 min
Read Time 1 min read

✓ Verified against BSE filing

Risk Intelligence

Material risks this quarter

Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.

Risks

R

Geopolitical uncertainty in Middle East

Ongoing conflict in the Middle East could disrupt supply chains, logistics, and demand, impacting near-term performance.

high · management_commentary
R

Raw material price volatility

March saw raw material price increases of 25-30%, which impacted gross margins; pass-through is ongoing but may face resistance in textiles.

medium · management_commentary
R

El Niño impact on agro season

El Niño could affect the agro season and demand for agrochemicals, though management says it's too early to comment.

medium · analyst_question
R

Execution risk in Saudi expansion

The Saudi initiative is a key strategic step but faces uncertainties from geopolitical developments and may take time to ramp up.

medium · management_commentary